NYSE:GSK - GlaxoSmithKline Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $39.99 -0.21 (-0.52 %) (As of 05/24/2019 01:00 AM ET)Previous Close$40.20Today's Range$39.82 - $40.0352-Week Range$36.41 - $42.36Volume1.85 million shsAverage Volume2.49 million shsMarket Capitalization$99.20 billionP/E Ratio12.66Dividend Yield4.95%Beta0.74 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology; and strategic alliance with Merck KGaA to jointly develop and commercialize M7824 (bintrafusp alfa), an investigational bifunctional fusion protein immunotherapy. GlaxoSmithKline plc also has a joint research collaboration with Fimbrion Therapeutics Inc. to develop a small molecule candidate for the treatment and prevention of urinary tract infections. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom. Receive GSK News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:GSK Previous Symbol CUSIPN/A CIK1131399 Webhttp://www.gsk.com/ Phone44-20-8047-5000Debt Debt-to-Equity Ratio6.92 Current Ratio0.72 Quick Ratio0.48Price-To-Earnings Trailing P/E Ratio12.66 Forward P/E Ratio13.70 P/E Growth2.03 Sales & Book Value Annual Sales$41.14 billion Price / Sales2.41 Cash Flow$4.2184 per share Price / Cash Flow9.48 Book Value$1.77 per share Price / Book22.59Profitability EPS (Most Recent Fiscal Year)$3.16 Net Income$4.84 billion Net Margins12.27% Return on Equity171.27% Return on Assets9.97%Miscellaneous Employees99,349 Outstanding Shares2,480,600,000Market Cap$99.20 billion Next Earnings Date7/24/2019 (Estimated) OptionableOptionable GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions What is GlaxoSmithKline's stock symbol? GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK." How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline? GlaxoSmithKline declared a quarterly dividend on Friday, May 3rd. Investors of record on Friday, May 17th will be given a dividend of $0.4953 per share on Thursday, July 11th. This represents a $1.98 annualized dividend and a yield of 4.95%. The ex-dividend date of this dividend is Thursday, May 16th. View GlaxoSmithKline's Dividend History. How were GlaxoSmithKline's earnings last quarter? GlaxoSmithKline plc (NYSE:GSK) issued its quarterly earnings data on Wednesday, May, 1st. The pharmaceutical company reported $0.79 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.66 by $0.13. The pharmaceutical company earned $9.98 billion during the quarter, compared to analysts' expectations of $9.86 billion. GlaxoSmithKline had a net margin of 12.27% and a return on equity of 171.27%. View GlaxoSmithKline's Earnings History. When is GlaxoSmithKline's next earnings date? GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for GlaxoSmithKline. What guidance has GlaxoSmithKline issued on next quarter's earnings? GlaxoSmithKline updated its FY 2019 earnings guidance on Wednesday, May, 1st. The company provided earnings per share (EPS) guidance of $1.38-1.44 for the period, compared to the Thomson Reuters consensus estimate of $2.91. What price target have analysts set for GSK? 18 Wall Street analysts have issued 12 month price targets for GlaxoSmithKline's stock. Their predictions range from $36.95 to $47.00. On average, they anticipate GlaxoSmithKline's share price to reach $41.39 in the next twelve months. This suggests a possible upside of 3.5% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline. What is the consensus analysts' recommendation for GlaxoSmithKline? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 1 sell rating, 13 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline. Has GlaxoSmithKline been receiving favorable news coverage? Press coverage about GSK stock has trended somewhat positive on Thursday, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GlaxoSmithKline earned a news sentiment score of 1.9 on InfoTrie's scale. They also gave news stories about the pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of GlaxoSmithKline's key competitors? Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), AbbVie (ABBV), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG). What other stocks do shareholders of GlaxoSmithKline own? Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Bank of America (BAC), General Electric (GE), Intel (INTC), Exxon Mobil (xom) and Gilead Sciences (GILD). Who are GlaxoSmithKline's key executives? GlaxoSmithKline's management team includes the folowing people: Ms. Emma N. Walmsley, CEO & Director (Age 49)Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)Mr. Jack Bailey, Pres of US PharmaceuticalsMs. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57) Who are GlaxoSmithKline's major shareholders? GlaxoSmithKline's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (0.70%), Renaissance Technologies LLC (0.58%), Hotchkis & Wiley Capital Management LLC (0.29%), Hotchkis & Wiley Capital Management LLC (0.29%), Federated Investors Inc. PA (0.16%) and Morgan Stanley (0.15%). View Institutional Ownership Trends for GlaxoSmithKline. Which major investors are selling GlaxoSmithKline stock? GSK stock was sold by a variety of institutional investors in the last quarter, including Chartwell Investment Partners LLC, Klingenstein Fields & Co. LLC, Northern Trust Corp, FMR LLC, Confluence Investment Management LLC, Hotchkis & Wiley Capital Management LLC, Hotchkis & Wiley Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for GlaxoSmithKline. Which major investors are buying GlaxoSmithKline stock? GSK stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Charles Schwab Investment Management Inc., Morgan Stanley, Hsbc Holdings PLC, Dimensional Fund Advisors LP, Sio Capital Management LLC, Foundry Partners LLC and CIBC Asset Management Inc. View Insider Buying and Selling for GlaxoSmithKline. How do I buy shares of GlaxoSmithKline? Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is GlaxoSmithKline's stock price today? One share of GSK stock can currently be purchased for approximately $39.99. How big of a company is GlaxoSmithKline? GlaxoSmithKline has a market capitalization of $99.20 billion and generates $41.14 billion in revenue each year. The pharmaceutical company earns $4.84 billion in net income (profit) each year or $3.16 on an earnings per share basis. GlaxoSmithKline employs 99,349 workers across the globe. What is GlaxoSmithKline's official website? The official website for GlaxoSmithKline is http://www.gsk.com/. How can I contact GlaxoSmithKline? GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected] MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)Community Ranking: 1.9 out of 5 ()Outperform Votes: 567 (Vote Outperform)Underperform Votes: 924 (Vote Underperform)Total Votes: 1,491MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Balance Sheet Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.